The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Elena Elefante - One of the best experts on this subject based on the ideXlab platform.

  • One year in review 2018: Systemic Vasculitis.
    Clinical and experimental rheumatology, 2018
    Co-Authors: Elena Elefante, Milena Bond, Sara Monti, Gemma Lepri, Elena Cavallaro, Mara Felicetti, Emanuele Calabresi, Chiara Posarelli, Rosaria Talarico, Luca Quartuccio
    Abstract:

    Systemic Vasculitis are heterogeneous, complex and disabling disorders. Following the previous annual reviews of this series, this paper gives a brief overview on current knowledge about recent literature on small- and large-vessel Systemic Vasculitis, with a specific focus on pathogenetic and clinical aspects, novel possible disease-related biomarkers and current and future therapies that are in the pipeline.

  • One year in review 2017: Systemic Vasculitis.
    Clinical and Experimental Rheumatology, 2017
    Co-Authors: Elena Elefante, Milena Bond, Sara Monti, Gemma Lepri, Rosaria Talarico, Luca Quartuccio, Chiara Baldini
    Abstract:

    Systemic Vasculitis is a group of heterogeneous, disabling disorders. Great interest has recently arisen in pathophysiology, clinical phenotypes and therapy of large- and small-vessel Vasculitis. The general work hypothesis has been to promote research focused on disease-related pathogenetic pathways, with the ultimate goal of identifying novel diagnostic and prognostic biomarkers, thus leading towards more effective targeted treatments. Following the previous annual reviews of this series, we will hereby provide a critical digest of the recent literature on small- and large-vessel Systemic Vasculitis, with a specific focus on novel possible disease-related biomarkers and their impact on current and future therapies.

  • Systemic Vasculitis and the lung.
    Current opinion in rheumatology, 2017
    Co-Authors: R Talarico, Elena Elefante, Simone Barsotti, Chiara Baldini, Chiara Tani, Marta Mosca
    Abstract:

    Purpose of review The purpose of this review is to provide a critical analysis of the recent literature on this topic, with particular focus on the most relevant studies published over the last year. Recent findings Many studies are published every year on the diagnosis, pathogenesis and treatment of pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated Vasculitis (AAV). The main subjects covered by this article are the pathogenesis, diagnosis and clinical aspects of lung involvement in ANCA-associated Vasculitis and non-ANCA-associated Vasculitis. Summary Lung involvement is a common feature in Systemic Vasculitis. The lungs are one of the most frequently involved organs in Systemic Vasculitis. In order to provide an update on the recent advances in the pathogenesis, clinical features and novel treatments of lung involvement in Systemic Vasculitis, a systematic MedLine search has been performed.Most of the data analyzed have confirmed that lung involvement seems to develop more frequently in patients with myeloperoxidase-ANCA-positive AAV, mainly in those with a diagnosis of microscopic polyangiitis (MPA), compared with patients with proteinase 3 ANCA-positive AAV. Moreover, among non-ANCA-associated Vasculitis lung involvement may represent a worrying complication of the disease, mainly when associated with vascular involvement.

  • One year in review: Systemic Vasculitis.
    Clinical and experimental rheumatology, 2016
    Co-Authors: Elena Elefante, Alessandra Tripoli, Francesco Ferro, Chiara Baldini
    Abstract:

    Systemic Vasculitis are complex and heterogenous disorders. During the past months great efforts have been made aimed at clarifying disease pathogenesis and at improving patient management and treatment. In this review we summarise the most important scientific contributions on Vasculitis pathogenesis, diagnostic tools and treatment published in 2015.

  • Systemic Vasculitis: an annual critical digest of the most recent literature.
    Clinical and experimental rheumatology, 2014
    Co-Authors: A. Della Rossa, Elena Elefante, Francesco Ferro, E. Cioffi, Alice Parma, R. Vagelli, Rosaria Talarico
    Abstract:

    Herewith we provide our annual digest of the recent literature on Systemic Vasculitis in which we reviewed all the articles published during the last 12 months on large-, medium- and small-vessel Vasculitis, and selected the most relevant studies regarding the epidemiology, pathogenesis and management of Systemic Vasculitis. In particular, we focused the attention on giant cell arteritis, ANCA-associated Vasculitis and cryoglobulinaemia.

Chiara Baldini - One of the best experts on this subject based on the ideXlab platform.

  • One year in review 2017: Systemic Vasculitis.
    Clinical and Experimental Rheumatology, 2017
    Co-Authors: Elena Elefante, Milena Bond, Sara Monti, Gemma Lepri, Rosaria Talarico, Luca Quartuccio, Chiara Baldini
    Abstract:

    Systemic Vasculitis is a group of heterogeneous, disabling disorders. Great interest has recently arisen in pathophysiology, clinical phenotypes and therapy of large- and small-vessel Vasculitis. The general work hypothesis has been to promote research focused on disease-related pathogenetic pathways, with the ultimate goal of identifying novel diagnostic and prognostic biomarkers, thus leading towards more effective targeted treatments. Following the previous annual reviews of this series, we will hereby provide a critical digest of the recent literature on small- and large-vessel Systemic Vasculitis, with a specific focus on novel possible disease-related biomarkers and their impact on current and future therapies.

  • Systemic Vasculitis and the lung.
    Current opinion in rheumatology, 2017
    Co-Authors: R Talarico, Elena Elefante, Simone Barsotti, Chiara Baldini, Chiara Tani, Marta Mosca
    Abstract:

    Purpose of review The purpose of this review is to provide a critical analysis of the recent literature on this topic, with particular focus on the most relevant studies published over the last year. Recent findings Many studies are published every year on the diagnosis, pathogenesis and treatment of pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated Vasculitis (AAV). The main subjects covered by this article are the pathogenesis, diagnosis and clinical aspects of lung involvement in ANCA-associated Vasculitis and non-ANCA-associated Vasculitis. Summary Lung involvement is a common feature in Systemic Vasculitis. The lungs are one of the most frequently involved organs in Systemic Vasculitis. In order to provide an update on the recent advances in the pathogenesis, clinical features and novel treatments of lung involvement in Systemic Vasculitis, a systematic MedLine search has been performed.Most of the data analyzed have confirmed that lung involvement seems to develop more frequently in patients with myeloperoxidase-ANCA-positive AAV, mainly in those with a diagnosis of microscopic polyangiitis (MPA), compared with patients with proteinase 3 ANCA-positive AAV. Moreover, among non-ANCA-associated Vasculitis lung involvement may represent a worrying complication of the disease, mainly when associated with vascular involvement.

  • One year in review: Systemic Vasculitis.
    Clinical and experimental rheumatology, 2016
    Co-Authors: Elena Elefante, Alessandra Tripoli, Francesco Ferro, Chiara Baldini
    Abstract:

    Systemic Vasculitis are complex and heterogenous disorders. During the past months great efforts have been made aimed at clarifying disease pathogenesis and at improving patient management and treatment. In this review we summarise the most important scientific contributions on Vasculitis pathogenesis, diagnostic tools and treatment published in 2015.

  • Systemic Vasculitis: a critical digest of the recent literature.
    Clinical and Experimental Rheumatology, 2013
    Co-Authors: Rosaria Talarico, Chiara Baldini, Chiara Tani, A. Della Rossa, Linda Carli, Stefano Bombardieri
    Abstract:

    Herewith we provide a critical digest of the recent literature on Systemic Vasculitis. In this manuscript, we reviewed all the articles published during the last 12 months on large-, medium- and small-vessel Vasculitis and selected the most relevant studies regarding the epidemiology, pathogenesis and management of Systemic Vasculitis. In particular we focused the attention on giant cell arteritis, ANCA-associated Vasculitis and cryoglobulinemia.

Rosaria Talarico - One of the best experts on this subject based on the ideXlab platform.

  • One year in review 2018: Systemic Vasculitis.
    Clinical and experimental rheumatology, 2018
    Co-Authors: Elena Elefante, Milena Bond, Sara Monti, Gemma Lepri, Elena Cavallaro, Mara Felicetti, Emanuele Calabresi, Chiara Posarelli, Rosaria Talarico, Luca Quartuccio
    Abstract:

    Systemic Vasculitis are heterogeneous, complex and disabling disorders. Following the previous annual reviews of this series, this paper gives a brief overview on current knowledge about recent literature on small- and large-vessel Systemic Vasculitis, with a specific focus on pathogenetic and clinical aspects, novel possible disease-related biomarkers and current and future therapies that are in the pipeline.

  • One year in review 2017: Systemic Vasculitis.
    Clinical and Experimental Rheumatology, 2017
    Co-Authors: Elena Elefante, Milena Bond, Sara Monti, Gemma Lepri, Rosaria Talarico, Luca Quartuccio, Chiara Baldini
    Abstract:

    Systemic Vasculitis is a group of heterogeneous, disabling disorders. Great interest has recently arisen in pathophysiology, clinical phenotypes and therapy of large- and small-vessel Vasculitis. The general work hypothesis has been to promote research focused on disease-related pathogenetic pathways, with the ultimate goal of identifying novel diagnostic and prognostic biomarkers, thus leading towards more effective targeted treatments. Following the previous annual reviews of this series, we will hereby provide a critical digest of the recent literature on small- and large-vessel Systemic Vasculitis, with a specific focus on novel possible disease-related biomarkers and their impact on current and future therapies.

  • Systemic Vasculitis: an annual critical digest of the most recent literature.
    Clinical and experimental rheumatology, 2014
    Co-Authors: A. Della Rossa, Elena Elefante, Francesco Ferro, E. Cioffi, Alice Parma, R. Vagelli, Rosaria Talarico
    Abstract:

    Herewith we provide our annual digest of the recent literature on Systemic Vasculitis in which we reviewed all the articles published during the last 12 months on large-, medium- and small-vessel Vasculitis, and selected the most relevant studies regarding the epidemiology, pathogenesis and management of Systemic Vasculitis. In particular, we focused the attention on giant cell arteritis, ANCA-associated Vasculitis and cryoglobulinaemia.

  • Systemic Vasculitis: a critical digest of the recent literature.
    Clinical and Experimental Rheumatology, 2013
    Co-Authors: Rosaria Talarico, Chiara Baldini, Chiara Tani, A. Della Rossa, Linda Carli, Stefano Bombardieri
    Abstract:

    Herewith we provide a critical digest of the recent literature on Systemic Vasculitis. In this manuscript, we reviewed all the articles published during the last 12 months on large-, medium- and small-vessel Vasculitis and selected the most relevant studies regarding the epidemiology, pathogenesis and management of Systemic Vasculitis. In particular we focused the attention on giant cell arteritis, ANCA-associated Vasculitis and cryoglobulinemia.

R. Van Vollenhoven - One of the best experts on this subject based on the ideXlab platform.

  • Mycophenolate mofetil in the treatment of SLE and Systemic Vasculitis: experience at a single university center
    Lupus, 2014
    Co-Authors: Cecilia Lourdudoss, R. Van Vollenhoven
    Abstract:

    Mycophenolate mofetil (MMF) is used off-label for Systemic lupus erythematosus (SLE) and Systemic Vasculitis. The study aim was to investigate clinical use and treatment results with MMF in patients with SLE and Systemic Vasculitis. This study included patients with SLE or Systemic Vasculitis with ongoing or previous MMF treatment. Data on treatment outcome were obtained through medical record reviews. A total of 135 of 648 (21%) patients with SLE and 43 of 455 (9%) patients with Systemic Vasculitis had ongoing or previous MMF treatment. Among SLE patients, the most common organ manifestation at baseline (treatment start) was renal involvement (50%). Most of the Systemic Vasculitis patients had Wegener’s granulomatosis (GPA) (65%). Median dose of MMF was 2000 mg/day. Glucocorticoid (GC) doses were significantly reduced during MMF treatment from 21.7 mg/day at baseline to 8.3 mg/day at 12 months (p 

  • THU0273 Mycophenolate Mofetil in SLE and Systemic Vasculitis: Treatment Outcome in a Large Referred Center
    Annals of the Rheumatic Diseases, 2013
    Co-Authors: Cecilia Lourdudoss, S. Jamil, R. Van Vollenhoven
    Abstract:

    Background Systemic lupus erythematosus (SLE) and Systemic Vasculitis are autoimmune diseases. SLE is of an unknown cause that occurs primarily in women and can involve many organs. Systemic Vasculitis is characterized by inflammatory destruction of the blood vessels and tissue necrosis, there are several types of Vasculitis classified by size of the affected blood vessels. Mycophenolate mofetil (MMF) is an immunosuppressive drug that is commonly used within the transplantation area, but also for autoimmune Systemic diseases such as SLE and Systemic Vasculitis. Objectives The aim of this study was to investigate the outcome of MMF in patients with SLE and Systemic Vasculitis. Methods This study included patients with SLE or Systemic Vasculitis with ongoing or previous MMF treatment at Karolinska University Hospital, Stockholm, Sweden. Data on specific information regarding disease and treatment was obtained through medical record review. Results Out of a total of 648 patients with SLE and 455 with Systemic Vasculitis; 135 patients (21%) with SLE and 43 patients (9%) with Vasculitis had ongoing or previous MMF treatment. The most common organ manifestation at baseline was renal involvement (50%) among SLE patients. Median MMF dose was 2g/day and glucocorticoids (GC) doses were significantly reduced during MMF treatment from 21.7 mg/day to 8.3 mg/day after 12 months. By physician assessment, 79% of the patients were good or moderate responders to MMF treatment after 12 months. The most common adverse events leading to discontinuation were side effects in the gastrointestinal tract (40%) and general side effects (30%). A “survival-on-drug” Kaplan-Meier curve showed that 40% of the patients remained on long-term MMF treatment. Conclusions MMF was used in 16% of all patients with SLE and Systemic Vasculitis. The treatment appeared to be effective with a reasonable survival-on-drug as well as a GC sparing effect for many patients with SLE or Systemic Vasculitis. Disclosure of Interest C. Lourdudoss: None Declared, S. Jamil: None Declared, R. van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB

Rimke Oostvogels - One of the best experts on this subject based on the ideXlab platform.

  • Systemic Vasculitis in myelodysplastic syndromes.
    The Netherlands journal of medicine, 2012
    Co-Authors: Rimke Oostvogels
    Abstract:

    The development of immunological abnormalities in various neoplasms is a rather common phenomenon. The prevalence of life-threatening Systemic Vasculitis in malignancy, however, is much lower. Nonetheless we found an unexpected frequency of several autoimmune manifestations, including Systemic Vasculitis, in certain myelodysplastic syndromes. We illustrate this finding with the case of a 43-year-old man with signs of polyarteritis nodosa-like Systemic Vasculitis during progression of chronic myelomonocytic leukaemia. Subsequently, we review the literature on the combination of myelodysplastic syndromes and Systemic Vasculitis and discuss the prognostic consequences, considerations for treatment and possible pathophysiological mechanisms.